Analytical Data
-
Gene name
ZRANB1
- Application
-
Alternative Names
(TRAF-binding domain-containing protein)(hTrabid)(Zinc finger Ran-binding domain-containing protein 1)
-
Species
Human
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9UGI0
-
Expression Region
1-708aa
-
Molecular Weight
88.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ZRANB1, or zinc finger RNA-binding 1, is a crucial protein involved in various cellular processes, including RNA metabolism, gene regulation, and DNA repair. Recent studies have highlighted its significant role in maintaining genome stability and its potential implications in cancer biology. Abnormal expression or mutations in ZRANB1 have been associated with several types of tumors, suggesting that it may function as a tumor suppressor or promoter depending on the context. Researchers have been particularly interested in the mechanisms through which ZRANB1 interacts with RNA and its involvement in splicing and RNA transport pathways. The recombinant expression of ZRANB1 has enabled scientists to investigate its structure and function in detail, facilitating the exploration of its RNA-binding domains and interaction partners. Understanding the biochemical properties of ZRANB1 through recombinant protein studies can provide insights into its regulatory functions and establish a foundation for therapeutic strategies targeting its pathways in cancer and other diseases. By utilizing techniques such as co-immunoprecipitation and RNA-sequencing, researchers aim to delineate the molecular networks involving ZRANB1, which may ultimately lead to novel approaches for diagnosing and treating malignancies linked to its dysregulation. The growing body of evidence underscores the importance of ZRANB1 in cellular homeostasis and its potential as a biomarker and therapeutic target in oncology.
